ELIXIR

In progress

Human papillomavirus (HPV) is responsible for the most common sexually transmitted infection that can cause serious damage to cervical cancer. In case of precancerous or advanced lesions, surgical removal of diagnosed or total genital lesions is recommended. Unfortunately, there is a recurrence of cancer after a few years. It is therefore urgent to develop an innovative treatment to eliminate these precancerous lesions. We propose a new RNA-based therapeutic strategy targeting both viral proteins and genes involved in the development of precancerous cells. The originality of this project lies in the synthesis of nanovectors based on porous silicon (SiPo) biocompatible, to encapsulate these RNA. This interdisciplinary project brings together GREMAN (INSA-CVL/ U.Tours/ CNRS) for the development of innovative nanovectors based on SiPo and the Centre de Biophysique Moléculaire (CBM CNRS/ Orléans) for the development of therapeutic RNA.

Project benefits

There are no benefits for this project at this time

People involved in the project

Project leader

No member partner

CBM CENTRE DE BIOPHYSIQUE MOLÉCULAIRE

Information of the project

Start of the project on01 / 09 / 2022


Strategic business lines

Matériaux et composants pour l'électronique


Referent of the project

Florentin BORÉ
Chargé de projets innovants

06 66 39 55 43

florentin.bore-ext@st.com

Centre-Val de Loire